Physician profile
Brandee Simpson
NPI 1528628567
$2,876.08
in general payments reported to CMS, 2019-2025
32 companies · $1,732 in 2025
The $1,732 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.13 · 2023: $32.13 · 2024: $1,067 · 2025: $1,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,949 · Education: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,948.64 |
| Education | $882.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $311.46 | 2024-2025 | |
| Lilly USA, LLC | $303.57 | 2024-2025 | Verzenio, Jaypirca |
| Aveo Pharmaceuticals, INC. | $212.30 | 2024-2025 | |
| Daiichi Sankyo INC. | $175.15 | 2024-2025 | Enhertu, Datroway, Vanflyta |
| Abbvie INC. | $166.84 | 2021-2025 | |
| Genentech USA, INC. | $163.37 | 2024-2025 | Phesgo, Gazyva, Venclexta |
| Astrazeneca Pharmaceuticals LP | $133.14 | 2021-2025 | Imfinzi, Lynparza, Calquence |
| Novartis Pharmaceuticals Corporation | $126.29 | 2024-2025 | |
| Incyte Corporation | $123.18 | 2024-2025 | Jakafi, Monjuvi |
| Sobi, INC | $116.79 | 2025 | |
| Jazz Pharmaceuticals INC. | $108.11 | 2025 | |
| Janssen Biotech, INC. | $104.41 | 2024-2025 | Erleada, Balversa, Akeega |
| Tersera Therapeutics LLC | $101.77 | 2024-2025 | Zoladex, Quzyttir |
| Seagen INC. | $99.99 | 2025 | |
| Merck Sharp & Dohme LLC | $73.49 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $65.50 | 2024-2025 | Fruzaqla |
| E.R. Squibb & Sons, L.L.C. | $44.18 | 2025 | Opdivo |
| Puma Biotechnology, INC. | $43.74 | 2024-2025 | |
| Eisai INC. | $42.64 | 2024-2025 | |
| Array Biopharma INC | $42.40 | 2025 | Lorbrena, Xalkori, Mektovi |
| Genmab U.S., INC. | $38.44 | 2024 | Epkinly |
| Blueprint Medicines Corporation | $35.38 | 2024 | Ayvakit |
| Dendreon Pharmaceuticals LLC | $35.04 | 2024-2025 | Provenge |
| Beone Medicines USA, INC. | $34.05 | 2025 | Brukinsa |
| Hologic Sales and Service, LLC | $32.13 | 2023 | Coolseal Generator, Acessa Provu System |
| Bayer Healthcare Pharmaceuticals INC. | $23.90 | 2025 | |
| Medtronic, INC. | $23.80 | 2025 | Synchromedii |
| Glaxosmithkline, LLC. | $21.63 | 2025 | Ojjaara, Blenrep |
| Servier Pharmaceuticals LLC | $20.57 | 2025 | |
| Deciphera Pharmaceuticals INC. | $20.23 | 2025 | Romvimza, Qinlock |
| Pharmacosmos Therapeutics INC. | $17.65 | 2025 | Monoferric |
| Azurity Pharmaceuticals, INC. | $14.94 | 2025 | Danziten |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandee Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.